I-Mab, Ferring team up to develop olamkicept for inflammatory bowel disease

Jun. 09, 2022 8:07 AM ETI-Mab (IMAB)By: Ravikash, SA News Editor

Business agreement

mediaphotos/iStock via Getty Images

  • Switzerland-based Ferring Pharmaceuticals said it entered a strategic collaboration with China's I-Mab (NASDAQ:IMAB) to further develop olamkicept in inflammatory bowel disease (IBD) and related inflammatory conditions.
  • Financial details were not undisclosed, as per the June 9 press release.
  • Ferring noted that it in 2016 it granted I-Mab exclusive rights to develop and commercialize olamkicept in Greater China and South Korea.
  • The new collaboration enables Ferring to invest in the development of olamkicept globally and provides an option for I-Mab to partner with Ferring in the future development of olamkicept at a pre-defined development milestone, said the company.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.